Risk-Benefit Assessment
The systematic evaluation of a drug's potential benefits against its potential risks that forms the basis of all regulatory approval decisions. A positive risk-benefit assessment means the expected therapeutic benefits outweigh the known and potential risks for the intended patient population.
Technical Context
Regulatory risk-benefit frameworks: FDA's Benefit-Risk Assessment Framework (structured approach across five dimensions — analysis of condition, current treatment options, benefit, risk, and risk management), EMA's benefit-risk methodology (based on the BRAT framework — Benefit-Risk Action Team), and ICH M4E(R2) (Common Technical Document clinical overview structure). Quantitative approaches include: number needed to treat vs number needed to harm, incremental net health benefit, and multi-criteria decision analysis (MCDA). For peptide drugs, key risk-benefit considerations include: therapeutic benefit magnitude, adverse event severity and frequency, availability of alternatives, disease severity, and patient population characteristics. The risk-benefit balance may differ by indication — semaglutide's risk-benefit is assessed differently for type 2 diabetes (where alternatives exist) vs rare obesity conditions (where fewer options are available).